Antitrust Suit Over Allergan Pink-Eye Meds Heads For Trial
An antitrust suit accusing Allergan Inc. of trying to extend the patent for its Zymar pink-eye treatment by marketing a nearly identical reformulation will continue to trial, a Delaware federal judge...To view the full article, register now.
Already a subscriber? Click here to view full article